RT Journal Article
SR Electronic
A1 Spevak, Aimee
T1 Evolocumab Effectively Lowers LDL-C, Decreases Cardiovascular Outcomes in OSLER
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 5
SP 10
OP 11
DO 10.1177/1559897715583660
UL http://mdc.sagepub.com/content/15/5/10.abstract
AB The OSLER extension studies randomized patients to receive standard of care or standard of care plus evolocumab. At 1 year, evolocumab lowered low-density lipoprotein cholesterol by 61% and demonstrated preliminary evidence that this may reduce the risk of cardiovascular events. Evolocumab was well tolerated across all gradients of achieved low-density lipoprotein cholesterol levels.